BackPDL Biopharma Overview

PDL Biopharma Net Tangible Assets

PDL Biopharma's net tangible assets is $590M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$593.20M
↓ 6.94% YoYΔ $-44.22M vs prior year quarter

Peer average / median

Loading

PDL Biopharma Net Tangible Assets History

Loading

PDL Biopharma vs. peers: Net Tangible Assets Comparison

Loading

PDL Biopharma Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PDL Biopharma (PDLI) FAQ

As of the most recent data (September 2020), PDLI shows a net tangible assets of $590M. That compares with $640M in the prior-year period — down 6.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PDLI's net tangible assets is now $590M (was $640M) — a 6.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PDL Biopharma is outperforming or lagging.

Tracking PDLI's net tangible assets over time shows whether PDL Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $590M That compares with $640M in the prior-year period — down 6.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has PDL Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $590M) with ownership activity and broader fundamentals.

PDL Biopharma's net tangible assets is $590M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.